Core Insights - Carillon Eagle Small Cap Growth Fund reported marginal gains in small-cap stocks for Q4 2025, with the Russell 2000 Growth Index returning 13.01% and the Value Index at 12.58% [1] - The firm anticipates a favorable year ahead for equity markets, highlighting potential opportunities in Cyclicals, Healthcare, Information Technology, Financials, and Consumer spending sectors heading into 2026 [1] Company Highlights: Establishment Labs Holdings Inc. (NASDAQ:ESTA) - Establishment Labs Holdings Inc. is recognized as a leading contributor to the fund, focusing on advanced breast implants and reconstructive plastic surgeries [2][3] - The stock closed at $74.60 on February 13, 2026, with an 8.35% return in the past month and a significant 102.73% increase over the past twelve months, giving it a market capitalization of $2.125 billion [2] - The company has seen robust demand following FDA approval in late 2024, with strong brand recognition and clinical advantages over competitors, positioning it for EBITDA profitability by late 2025 or early 2026 [3] - Establishment Labs is expected to achieve cash flow positivity in 2026, supported by a recent FDA application for its implant for primary and revision breast reconstruction [3] Market Position - Establishment Labs Holdings Inc. was held by 29 hedge fund portfolios at the end of Q3 2025, indicating a slight increase from 28 in the previous quarter [4] - Despite its potential, the company is not among the 30 most popular stocks among hedge funds, with some analysts suggesting that certain AI stocks may offer greater upside potential with less downside risk [4]

Core Insights - Medtronic plc (MDT) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.36, a decrease of 2.2% year-over-year, but exceeded the Zacks Consensus Estimate by 2.07% [1] - The company achieved worldwide revenues of $9.02 billion, reflecting an 8.7% increase year-over-year and surpassing the Zacks Consensus Estimate by 1.35% [2] Revenue Breakdown - MDT's revenues are categorized into four segments: Cardiovascular, Medical Surgical, Neuroscience, and Diabetes - Cardiovascular revenues grew 10.6% organically to $3.46 billion, with Cardiac Rhythm & Heart Failure sales reaching $1.86 billion, up 17% year-over-year [3][4] - Medical Surgical sales totaled $2.17 billion, up 2.7% year-over-year, with Acute Care & Monitoring revenues increasing by 7% to $519 million [5] - Neuroscience revenues were $2.56 billion, up 2.5% year-over-year, while Diabetes revenues rose 8.3% organically to $796 million [6] Margin Performance - The gross margin contracted by 265 basis points to 63.8%, attributed to a 17.3% increase in the cost of products sold [7] - Research and development expenses rose 7% year-over-year to $722 million, and selling, general, and administrative expenses increased by 8.8% to $2.96 billion [7] - The adjusted operating margin fell by 253 basis points year-over-year to 23% [7] Fiscal Outlook - For fiscal 2026, Medtronic projects organic revenue growth of 5.5%, with the Zacks Consensus Estimate for worldwide revenues at $36.04 billion [8] - The full-year adjusted EPS is expected to be in the range of $5.62-$5.66, consistent with the Zacks Consensus Estimate of $5.64 [10] Strategic Developments - During the quarter, Medtronic received CE Mark for Sphere-360 and FDA clearance for Hugo robotic-assisted surgery [12] - The company executed its M&A strategy with two key transactions involving CathWorks and Anteris [12] Stock Performance - Following the earnings announcement, MDT shares rose by 2.9% in premarket trading [2] - The overall performance indicates strength in the portfolio, with organic revenue growth exceeding company guidance [11]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

Medical technology stock Masimo Corp (NASDAQ:MASI) is soaring today, last seen up 34.3% to trade at $174.78, after reports that the company is nearing an agreement to be acquired by Danaher Corp (NYSE:DHR) in an all-cash deal worth roughly $10 billion. DHR, on the other hand, is down 4% to trade at $204.12 after the news. On track for its largest single-day percentage gain on record, MASI is gapping to its highest levels since June. Year over year, however, the equity is still hanging on to a 3.7% deficit.  ...

Core Insights - Medtronic reported $9.02 billion in revenue for the quarter ended January 2026, marking an 8.7% year-over-year increase and a surprise of +1.35% over the Zacks Consensus Estimate of $8.9 billion [1] - The earnings per share (EPS) for the same period was $1.36, slightly down from $1.39 a year ago, with an EPS surprise of +2.07% compared to the consensus estimate of $1.33 [1] Revenue Breakdown - U.S. Revenue: $4.49 billion, a 6% year-over-year increase, but below the average estimate of $4.59 billion [4] - International Revenue: $4.52 billion, exceeding the average estimate of $4.3 billion [4] - Cardiovascular Revenue: $3.46 billion, a 13.8% year-over-year increase, surpassing the average estimate of $3.39 billion [4] - Neuroscience Revenue: $2.56 billion, a 4.1% year-over-year increase, slightly below the average estimate of $2.58 billion [4] - Medical Surgical Revenue: $2.17 billion, a 4.9% year-over-year increase, exceeding the average estimate of $2.14 billion [4] - Diabetes Revenue: $796 million, a 14.7% year-over-year increase, surpassing the average estimate of $773.73 million [4] - Cardiac Rhythm & Heart Failure Revenue: $1.86 billion, a significant 20.1% year-over-year increase, exceeding the average estimate of $1.8 billion [4] Stock Performance - Medtronic shares have returned +2.8% over the past month, contrasting with a -1.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Medtronic Just Posted Its Best Quarter in 2.5 Years - 24/7 Wall St.[S&P 5006,801.40 -0.57%][Dow Jones49,305.60 -0.48%][Nasdaq 10024,498.60 -0.73%][Russell 20002,624.86 -0.54%][FTSE 10010,519.70 +0.48%][Nikkei 22556,668.00 -0.19%][Stock Market Live February 17, 2026: S&P 500 (ETF) Fighting to Go Green Again][Investing]# Medtronic Just Posted Its Best Quarter in 2.5 Years### Quick ReadMedtronic (MDT) delivered its strongest revenue growth in 10 quarters and beat Wall Street on revenue and earnings.Medtronic's ...

Core Insights - Tandem Diabetes Care, Inc. (TNDM) is expected to report a quarterly loss of -$0.05 per share, marking an 88.6% increase in loss compared to the same period last year [1] - Analysts forecast revenues of $276 million, reflecting a year-over-year increase of 9.3% [1] - The consensus EPS estimate has been adjusted downward by 0.8% over the past 30 days, indicating a reassessment by covering analysts [1] Revenue Estimates - Analysts project 'Revenue- Supplies and Other' to reach $141.55 million, indicating a year-over-year change of +10.4% [4] - The consensus for 'Revenue- Pump' is estimated at $134.50 million, showing an increase of +8.3% from the prior-year quarter [4] - 'Sales- Pump- United States' is expected to be $108.34 million, reflecting a year-over-year change of +10.1% [4] Geographic Sales Projections - 'Sales- Pump- Outside the United States' is estimated to be $26.16 million, indicating a +1.5% change from the year-ago quarter [5] - 'Sales- Supplies and Other- United States' is forecasted to reach $94.74 million, with a year-over-year change of +10.3% [5] - The estimated 'Geographic Sales- United States' stands at $203.09 million, reflecting a year-over-year change of -5.4% [5] International Sales Estimates - 'Sales- Supplies and Other- Outside the United States' is projected at $46.80 million, indicating a +10.6% change from the prior-year quarter [6] - The consensus for 'Geographic Sales- Outside the United States' is $72.94 million, showing a significant decline of -99.9% from the year-ago quarter [6] Pump Shipments Forecast - Total worldwide 'Pump Shipments' are expected to reach 35,032, compared to 34,000 in the same quarter last year [7] - 'Pump Shipments- Outside the United States' is projected at 9,400, down from 10,000 in the previous year [7] - 'Pump Shipments- United States' is estimated at 25,632, compared to 24,000 in the year-ago period [7] Stock Performance - Over the past month, shares of Tandem Diabetes Care have returned -6%, while the Zacks S&P 500 composite has changed by -1.4% [8] - TNDM currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [8]

Group 1: Market Overview - US stocks experienced volatility with the Nasdaq Composite falling 0.1% and the S&P 500 also shedding approximately 0.1%, while the Dow Jones Industrial Average remained stable above the flatline [1] - Concerns regarding AI's impact on various industries have led to a decline in the Dow and S&P 500, which have fallen in four of the past five weeks [2] Group 2: Earnings Reports - The final stretch of earnings season is underway, with Constellation Energy's results being closely watched for insights on AI's influence on energy demand, alongside reports from Medtronic and Palo Alto Networks [3] - Walmart's quarterly report, the first since reaching a trillion-dollar market cap, is anticipated as a highlight of the week [3] Group 3: Corporate Developments - Paramount Skydance's stock rose over 5% following news that Warner Bros. Discovery has requested a better offer from the studio after rejecting its latest bid [4] Group 4: Economic Indicators - A series of economic readings, including the delayed December Personal Consumption Expenditures index, are expected to be released, particularly after a cooler-than-expected consumer inflation report [5] - An advance look at fourth quarter GDP is scheduled for release, which will provide insights into economic health amid discussions on interest-rate cuts [6]

Earnings Reports Overview - The fourth-quarter earnings season is nearing its end, with several significant reports from retail, energy, and tech companies expected this week [1] - Key companies reporting include Palo Alto Networks, Carvana, Walmart, and Opendoor Technologies [1][2][4][7] Company-Specific Insights - **Palo Alto Networks**: Expected to report earnings of 94 cents per share on revenue of $2.58 billion [1] - **Carvana**: Anticipated to report quarterly earnings of $1.10 per share on revenue of $5.26 billion, despite concerns over a short-seller report alleging accounting irregularities [3] - **Walmart**: Projected to report earnings of 72 cents per share on revenue of $190.24 billion, with a focus on high-margin segments like advertising and e-commerce [4] - **Opendoor Technologies**: Investors are looking for updates on turnaround plans and progress toward 2026 profitability, particularly regarding gross margins and the AI-driven "capital-light" platform [7]

Financial Data and Key Metrics Changes - The company reported revenue of $9 billion, reflecting an 8.7% increase year-over-year and a 6% organic growth, which is a 50 basis point acceleration from the previous quarter [18][19] - Adjusted gross margin was 64.9%, ahead of expectations, with a 30 basis point benefit from pricing [19][20] - Adjusted operating profit was $2.2 billion, resulting in an adjusted operating margin of 24.1%, also ahead of expectations [21] Business Line Data and Key Metrics Changes - The cardiovascular portfolio delivered 11% year-over-year revenue growth, with 13% growth in the U.S., marking the strongest growth in the last 10 years, excluding COVID comparisons [12] - Cardiac rhythm management (CRM) contributed 15% of total revenue and grew 5%, driven by double-digit growth in Micra and over 70% growth in Aurora EV-ICD [12][13] - The neuroscience portfolio grew 3%, with expectations for the pipeline to impact growth in the fourth quarter [14][15] Market Data and Key Metrics Changes - U.S. growth was 6% year-over-year, the strongest performance since fiscal year 2019, excluding COVID comparisons [19] - In China, low single-digit growth was reported while navigating volume-based procurement challenges [19] - Western Europe experienced high single-digit growth, contributing to balanced geographical performance [19] Company Strategy and Development Direction - The company is focused on expanding its innovation pipeline, particularly in high-growth areas such as hypertension treatment with Symplicity and urinary incontinence with Altaviva [2][3] - The launch of the Hugo robotic system is seen as a significant growth driver, with initial installations and positive feedback from early cases [5][6] - The company is committed to M&A strategies, focusing on tuck-in deals that align with existing business segments [59][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining revenue and earnings growth, highlighting strong contributors like CAS and CRM [10][24] - The company anticipates continued growth from new product launches and market expansions, particularly in the U.S. [10][39] - There is an expectation for high single-digit EPS growth in fiscal year 2027, despite some headwinds from tariffs and M&A activities [24][68] Other Important Information - The planned separation of the MiniMed diabetes business is on track, with expectations for completion by the end of calendar year 2026 [18] - The company is investing in R&D and marketing to support growth areas, particularly in renal denervation and Altaviva [66] Q&A Session Summary Question: Comments on accelerating revenue growth next year and high single-digit earnings growth - Management indicated that growth will continue, driven by strong performance in CAS and other growth drivers like Symplicity and Altaviva [30][39] Question: Monitoring progress for RDN and Altaviva - Management mentioned strong leading indicators, including training of over 500 physicians and opening of new accounts for RDN [43] Question: Thoughts on capital allocation and M&A strategy - The company is focused on tuck-in M&A opportunities that align with existing business segments, prioritizing high-growth areas [59][60] Question: Impact of Hugo on surgical business growth - Management expressed excitement about the Hugo system's potential, noting positive feedback from initial cases and strong leading indicators [87]